Anthony M. Nicasio, Pharm.D.
Infectious Diseases Pharmacotherapy Fellowship, Center for Anti-Infective Research and Development, Hartford, CT
Infectious Diseases Pharmacy Resident, Center for Anti-Infective Research and Development & Hartford Hospital, Hartford, CT
Pharm.D., University of Michigan, Ann-Arbor, MI
Courses Taught at ACPHS
PTPM (Infectious Disease Module)
Integrated Problem Solving
Dr. Nicasio’s research focuses on ways of optimizing antibiotic efficacy when used to treat prevalent multi-drug resistant bacterial infections. Specifically, he utilizes various experimental methodologies to evaluate the impact that antibiotic dosing strategies (e.g., pharmacokinetic-pharmacodynamic principles and combination therapy) have on the rate and extent of bacterial kill, the development of antibiotic resistance, and the survival of the patient.
Honors and Achievements
Infectious Diseases Society of America & Interscience Conference on Antimicrobial Agents and Chemotherapy Fellows Travel Grant Recipient. Awarded to infectious diseases fellows in recognition of excellence in abstract submission to the Annual Meeting (2008).
Making a Difference in Infectious Diseases Pharmacotherapy Abstract Award Recipient. Awarded to an infectious diseases fellow or resident in recognition of excellence in abstract submission to the MAD-ID Annual Meeting (2008).
The #1 viewed article in the peer-reviewed journal, Pharmacotherapy, in 2008, as cited in the ACCP Report 2009; 28 (2): 1-19.
Selected Peer-Reviewed Publications (Original Research)
Wiskirchen DE, Koomanachai P, Nicasio AM, Nicolau DP, Kuti JL. In vitro pharmacodynamics of simulated pulmonary exposures of tigecycline alone and in combination against Klebsiella pneumoniae isolates producing a KPC carbapenemase. Antimicrobial Agents and Chemotherapy. 2011;55(4):1420-7.
Crandon JL, Ariano RE, Zelenitsky SA, Nicasio AM, Kuti JL, Nicolau DP. Optimization of meropenem dosage in the critically ill population based on renal function.Intensive Care Medicine. 2011;37(4):632-8.
Nicasio AM, Eagye KJ, Kuti EL, Nicolau DP, Kuti JL. Hospital costs and length of stay associated with a pharmacodynamic based clinical pathway for empiric antibiotic choice in patients with ventilator associated pneumonia. Pharmacotherapy. 2010;30(5):453-62.
Nicasio AM, Eagye KJ, Nicolau DP, Shore E, Palter M, Pepe J, Kuti JL. A pharmacodynamic based clinical pathway for empiric antibiotic choice in patients infected with ventilator associated pneumonia. Journal of Critical Care. 2010;25:69-77.
Nicasio AM, Crandon JL, Nicolau DP. In vivo pharmacodynamic profile of tigecycline against phenotypically diverse Escherichia coli and Klebsiella pneumoniae. Antimicrobial Agents and Chemotherapy. 2009;53(7):2756-61.
Kuti JL, Nicasio AM, Sutherland CA, Nicolau DP. Elevated vancomycin minimum inhibitory concentrations among methicillin-resistant Staphylococcus aureus causing ventilator associated pneumonia at a Connecticut Hospital. Connecticut Medicine. 2009; 73(6):337-40.
Nicasio AM, Ariano RE, Zelenitsky SA, Kim A, Crandon JL, Kuti JL, Nicolau DP. Population pharmacokinetics of high-dose, prolonged-infusion cefepime in adult critically-ill patients with ventilator associated pneumonia. Antimicrobial Agents and Chemotherapy. 2009;53(4):1476-81.
Nicasio AM, Tessier PT, Nicolau DP, Knauft RF, Russomanno J, Shore E, Kuti JL. Bronchopulmonary disposition of micafungin in healthy adult volunteers. Antimicrobial Agents and Chemotherapy. 2009; 53(3):1218-20.
Nicasio AM, Kuti JL, Aslanzadeh J, Nicolau DP. Influence of automated testing and identification on extended spectrum β-lactamase producing Enterobacteriaceae on antibiotic prescribing. Journal of Medical Microbiology. 2008; 57(Pt9):1147-51.